ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager

ADC Therapeutics SA

NYSE:ADCT

Watchlist

Dividends

Price: 2.22 USD 9.36% Market Closed

Market Cap: 214.7m USD

Have any thoughts about
ADC Therapeutics SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

Add Price Alert

Price Target:

Last Price: 2.22 USD

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

ADCT Alert

ADC Therapeutics SA

2.22

+0.19 (+9.36%)

52 Week Range	0.7235 5.29
Price Target

We'll email you a reminder when the closing price reaches USD.

Save Alert

Choose the stock you wish to monitor with a price alert.

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

ADC Therapeutics SA

What unique competitive advantages
does ADC Therapeutics SA hold over its rivals?

What risks and challenges
does ADC Therapeutics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of ADC Therapeutics SA.

What unique competitive advantages
does ADC Therapeutics SA hold over its rivals?

What risks and challenges
does ADC Therapeutics SA face in the near future?

Has there been any significant insider trading activity
in ADC Therapeutics SA recently?

Summarize the latest earnings call
of ADC Therapeutics SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ADC Therapeutics SA.

Provide P/S
for ADC Therapeutics SA.

Provide P/E
for ADC Therapeutics SA.

Provide P/OCF
for ADC Therapeutics SA.

Provide P/FCFE
for ADC Therapeutics SA.

Provide P/B
for ADC Therapeutics SA.

Provide EV/S
for ADC Therapeutics SA.

Provide EV/GP
for ADC Therapeutics SA.

Provide EV/EBITDA
for ADC Therapeutics SA.

Provide EV/EBIT
for ADC Therapeutics SA.

Provide EV/OCF
for ADC Therapeutics SA.

Provide EV/FCFF
for ADC Therapeutics SA.

Provide EV/IC
for ADC Therapeutics SA.

Show me price targets
for ADC Therapeutics SA made by professional analysts.

What are the Revenue projections
for ADC Therapeutics SA?

How accurate were the past Revenue estimates
for ADC Therapeutics SA?

What are the Net Income projections
for ADC Therapeutics SA?

How accurate were the past Net Income estimates
for ADC Therapeutics SA?

What are the EPS projections
for ADC Therapeutics SA?

How accurate were the past EPS estimates
for ADC Therapeutics SA?

What are the EBIT projections
for ADC Therapeutics SA?

How accurate were the past EBIT estimates
for ADC Therapeutics SA?

Compare the revenue forecasts
for ADC Therapeutics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ADC Therapeutics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ADC Therapeutics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of ADC Therapeutics SA compared to its peers.

Compare the P/E ratios
of ADC Therapeutics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing ADC Therapeutics SA with its peers.

Analyze the financial leverage
of ADC Therapeutics SA compared to its main competitors.

Show all profitability ratios
for ADC Therapeutics SA.

Provide ROE
for ADC Therapeutics SA.

Provide ROA
for ADC Therapeutics SA.

Provide ROIC
for ADC Therapeutics SA.

Provide ROCE
for ADC Therapeutics SA.

Provide Gross Margin
for ADC Therapeutics SA.

Provide Operating Margin
for ADC Therapeutics SA.

Provide Net Margin
for ADC Therapeutics SA.

Provide FCF Margin
for ADC Therapeutics SA.

Show all solvency ratios
for ADC Therapeutics SA.

Provide D/E Ratio
for ADC Therapeutics SA.

Provide D/A Ratio
for ADC Therapeutics SA.

Provide Interest Coverage Ratio
for ADC Therapeutics SA.

Provide Altman Z-Score Ratio
for ADC Therapeutics SA.

Provide Quick Ratio
for ADC Therapeutics SA.

Provide Current Ratio
for ADC Therapeutics SA.

Provide Cash Ratio
for ADC Therapeutics SA.

What is the historical Revenue growth
over the last 5 years for ADC Therapeutics SA?

What is the historical Net Income growth
over the last 5 years for ADC Therapeutics SA?

What is the current Free Cash Flow
of ADC Therapeutics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for ADC Therapeutics SA.

P/S
Price to Sales

1.7

Current

2.4

Median

7.7

Industry

Lower than median

Lower than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S

1.7

Market Cap

214.6m USD

Revenue

123.5m USD

All Countries

Forward Multiples

			Market Cap	P/S
CH		ADC Therapeutics SA NYSE:ADCT	214.6m USD	1.7
FR		Pharnext SCA OTC:PNEXF	6T USD	37 797 580.3
US		Abbvie Inc NYSE:ABBV	320.1B USD	5.8
US		Amgen Inc NASDAQ:AMGN	147.4B USD	4.5
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	119.4B USD	11.2
US		Gilead Sciences Inc NASDAQ:GILD	113.8B USD	4
US	E	Epizyme Inc F:EPE	94.1B EUR	1 863.9
AU		CSL Ltd ASX:CSL	135.4B AUD	5.9
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	82.6B USD	6
US	S	Seagen Inc F:SGT	39.3B EUR	18
NL		argenx SE XBRU:ARGX	34.3B EUR	18.5

				Revenue Growth
CH		ADC Therapeutics SA NYSE:ADCT	Average P/S: 3 436 320 1.7	71%
FR		Pharnext SCA OTC:PNEXF	37 797 580.3	N/A
US		Abbvie Inc NYSE:ABBV	5.8	20%
US		Amgen Inc NASDAQ:AMGN	4.5	26%
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	11.2	33%
US		Gilead Sciences Inc NASDAQ:GILD	4	10%
US	E	Epizyme Inc F:EPE	1 863.9	N/A
AU		CSL Ltd ASX:CSL	5.9	23%
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	6	23%
US	S	Seagen Inc F:SGT	18	118%
NL		argenx SE XBRU:ARGX	18.5	220%

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/S

2.9

2-Years Forward

P/S

2.5

3-Years Forward

P/S

1.8

ADC Therapeutics SA
NYSE:ADCT

P/S
Price to Sales

P/S Forward Multiples

See Also

Company

Help

Tools

Stocks

ADC Therapeutics SA NYSE:ADCT

P/S Price to Sales

P/S Forward Multiples

See Also

Company

Help

Tools

Stocks

ADC Therapeutics SA
NYSE:ADCT

P/S
Price to Sales